C-Reactive Protein Levels in Schizophrenia: A Review and Meta-Analysis
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
There is an impression in the literature that schizophrenia is associated with increased inflammation, including abnormal blood levels of the acute phase reactant C-reactive protein (CRP). We performed a meta-analysis of blood CRP levels to estimate the overall effect size, as well as a pooled analysis of the prevalence of an elevated CRP level in patients with schizophrenia and related disorders. We identified articles by searching PubMed, PsycInfo, and ISI, and the reference lists of identified studies. Eight studies met the inclusion criteria for the meta-analysis, and five studies were included in the pooled analysis. CRP levels were significantly increased in patients compared to controls (effect size=0.45, 95% confidence interval 0.34-0.55, p<0.001). There was a 28% prevalence of an elevated CRP level in patients with schizophrenia and related disorders. Our results support a growing body of literature that schizophrenia is associated with increased inflammation, although many studies did not control for potential confounding factors such as BMI and smoking. Given the high prevalence of elevated CRP, metabolic syndrome, and premature cardiovascular mortality, our findings also suggest that measurement of blood CRP levels may be germane to the clinical care of patients with schizophrenia and related disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.
Howren, M. B., Lamkin, D. M., & Suls, J. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181907c1b · Cited by 2,766
Saha, S., Chant, D., & McGrath, J. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1123 · Cited by 2,065
Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects
Miller, B. J., Buckley, P., Seabolt, W., Mellor, A., & Kirkpatrick, B. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.013 · Cited by 1,742
Self-citationMetabolic Syndrome and Risk of Cardiovascular Disease: A Meta-Analysis
Galassi, A., Reynolds, K., & He, J. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.02.031 · Cited by 1,207
McEvoy, J. P., Meyer, J. M., Goff, D. C., Nasrallah, H. A., Davis, S. M., Sullivan, L., Meltzer, H. Y., Hsiao, J., Scott Stroup, T., & Lieberman, J. A. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.014 · Cited by 1,140
Hunter, J. E., & Schmidt, F. L. (2000) · International Journal of Selection and Assessment · doi:10.1111/1468-2389.00156 · Cited by 833
Cytokines and schizophrenia: microglia hypothesis of schizophrenia
Monji, A., Kato, T., & Kanba, S. (2009) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2009.01945.x · Cited by 508
Cited by
Inflammation and Schizophrenia
Kirkpatrick, B., & Miller, B. J. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt141 · Cited by 312
Self-citationInflammatory Biomarkers and Risk of Schizophrenia: A 2-Sample Mendelian Randomization Study
Hartwig, F. P., Borges, M. C., Horta, B. L., Bowden, J., & Davey Smith, G. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3191 · Cited by 302
Henderson, D. C., Vincenzi, B., Andrea, N. V., Ulloa, M., & Copeland, P. M. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00115-7 · Cited by 288
Costello, H., Gould, R. L., Abrol, E., & Howard, R. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-027925 · Cited by 248
Prins, B. P., Abbasi, A., Wong, A., Vaez, A., Nolte, I., Franceschini, N., Stuart, P. E., Guterriez Achury, J., Mistry, V., Bradfield, J. P., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001976 · Cited by 199
“In contrast, others have previously shown that CRP levels are significantly elevated in patients with schizophrenia [69,70], with a recent meta-analysis concluding Effect size (95% CI) per 1-mg/l increase in lnCRP.”
ResultMazza, M. G., Lucchi, S., Rossetti, A., & Clerici, M. (2020) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2019.1583371 · Cited by 191
Pillinger, T., Osimo, E. F., Brugger, S., Mondelli, V., McCutcheon, R. A., & Howes, O. D. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sby160 · Cited by 190
“…lines of evidence, including genetic, postmortem, and preclinical data, suggest immune dysregulation may play a role in psychosis pathogenesis.4–22 Supporting this, meta-analyses have shown raised levels of soluble interleukin-2 receptor (sIL2R), interleukin-6 (IL6), interleukin-8 (IL8),…”
Neutrophil-to-lymphocyte ratio in schizophrenia: A systematic review and meta-analysis
Karageorgiou, V., Milas, G. P., & Michopoulos, I. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2018.12.017 · Cited by 163
Early interventions in risk groups for schizophrenia: what are we waiting for?
Sommer, I. E., Bearden, C. E., van Dellen, E., Breetvelt, E. J., Duijff, S. N., Maijer, K., van Amelsvoort, T., de Haan, L., Gur, R. E., Arango, C., et al. (2016) · npj Schizophrenia · doi:10.1038/npjschz.2016.3 · Cited by 140
Khandaker, G. M., Zammit, S., Burgess, S., Lewis, G., & Jones, P. B. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.11.020 · Cited by 118
Associations of high sensitivity C-reactive protein levels in schizophrenia and comparison groups
Joseph, J., Depp, C., Martin, A. S., Daly, R. E., Glorioso, D. K., Palmer, B. W., & Jeste, D. V. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.08.019 · Cited by 109
“Ameta-analysis of eight studies found that CRP levels were higher in people with schizophrenia than in comparison subjects (Miller et al., 2014).”
Lee, E. E., Hong, S., Martin, A. S., Eyler, L. T., & Jeste, D. V. (2017) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2016.09.009 · Cited by 94
Balcioglu, Y. H., & Kirlioglu, S. S. (2020) · Psychiatry Investigation · doi:10.30773/pi.2020.0185 · Cited by 80
Vincenzi, B., Stock, S., Borba, C. P. C., Cleary, S. M., Oppenheim, C. E., Petruzzi, L. J., Fan, X., Copeland, P. M., Freudenreich, O., Cather, C., et al. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.08.021 · Cited by 67
“…(IL-6), are the primary inducers of acute phase proteins, including C-reactive protein (CRP) which is an acute phase protein produced by hepatocytes whose serum concentration increases under acute and chronic inflammatory conditions (Black et al., 2004; Agrawal, 2005; Miller et al., 2014).”
BackgroundQuidé, Y., Bortolasci, C. C., Spolding, B., Kidnapillai, S., Watkeys, O. J., Cohen-Woods, S., Carr, V. J., Berk, M., Walder, K., & Green, M. J. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110013 · Cited by 44
van Velzen, L. S., Schmaal, L., Milaneschi, Y., van Tol, M.-J., van der Wee, N. J. A., Veltman, D. J., & Penninx, B. W. J. H. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.10.019 · Cited by 38
Metadata
- Authors
- Miller, B. J., Culpepper, N., & Rapaport, M. H.
- Venue
- Clinical Schizophrenia & Related Psychoses
- Publisher
- Longdom Group
- Published
- 2014-01
- Volume
- 7
- Issue
- 4
- Pages
- 223-230
- ISSN
- 1935-1232 (ISSN-L)
- OpenAlex
- W2179568988
- Cited by
- 267
- References
- 48
- FWCI
- 12.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.